Latest & greatest articles for migraine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on migraine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on migraine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for migraine

161. Rizatriptan for acute migraine headaches in adults.

Rizatriptan for acute migraine headaches in adults. This is the protocol for a review and there is no abstract. The objectives are as follows: The objective of the review will be to determine the efficacy and tolerability of rizatriptan compared to placebo and other active interventions in the treatment of acute migraine headaches in adults.

Cochrane2010

162. Eletriptan for acute migraine headaches in adults.

Eletriptan for acute migraine headaches in adults. This is the protocol for a review and there is no abstract. The objectives are as follows: The objective of the review will be to determine the efficacy and tolerability of eletriptan compared to placebo and other active interventions in the treatment of acute migraine headaches in adults.

Cochrane2010

163. Migraine headache in middle age and late-life brain infarcts.

Migraine headache in middle age and late-life brain infarcts. CONTEXT: Migraine is considered to be an episodic condition with no long-term consequences. However, recent studies suggest that migraine attacks may be associated with pathologic changes in the brain, particularly in the cerebellum. OBJECTIVE: To determine whether individuals not reporting headache compared with individuals reporting migraine symptoms, particularly aura, in midlife are at increased risk of late-life infarct-like (...) lesions found on magnetic resonance imaging (MRI) without consideration of clinical symptoms. DESIGN, SETTING, AND PARTICIPANTS: A population-based study of men and women in Reykjavik, Iceland (cohort born 1907-1935; n = 4689; 57% women) were followed up since 1967, examined, and interviewed about migraine symptoms in midlife (mean age, 51 years; range, 33-65 years). Between 2002 and 2006, more than 26 years later, brain MRIs were performed. Participants reporting headaches once or more per month were

JAMA2009 Full Text: Link to full Text with Trip Pro

164. Migraine is a risk factor for hypertensive disorders in pregnancy: a prospective cohort study

Migraine is a risk factor for hypertensive disorders in pregnancy: a prospective cohort study 19220309 2009 02 17 2009 04 30 2009 02 17 1468-2982 29 3 2009 Mar Cephalalgia : an international journal of headache Cephalalgia Migraine is a risk factor for hypertensive disorders in pregnancy: a prospective cohort study. 286-92 10.1111/j.1468-2982.2008.01704.x The aim was to assess whether women suffering from migraine are at higher risk of developing hypertensive disorders in pregnancy (...) . In a prospective cohort study, performed at antenatal clinics in three maternity units in Northern Italy, 702 normotensive women with singleton pregnancy at 11-16 weeks' gestation were enrolled. Women with a history of hypertensive disorders in pregnancy or presenting chronic hypertension were excluded. The presence of migraine was investigated according to International Headache Society criteria. The main outcome measure was the onset of hypertension in pregnancy, defined as the occurrence of either

EvidenceUpdates2009

165. Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study.

Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study. OBJECTIVE: To examine the association between migraine and cardiovascular diseases during pregnancy. Design US population based case-control study. SETTING: Nationwide inpatient sample, from the Healthcare Cost and Utilization Project of the Agency for Healthcare Research and Quality. Population 18,345,538 pregnancy related discharges from 2000 to 2003. MAIN OUTCOME MEASURES: Diagnosis (...) of migraine, as identified by ICD-9 codes 346.0 and 346.1. Stroke and other vascular diseases were identified by using standard ICD-9 codes. RESULTS: From the hospital discharges with a pregnancy discharge code, 33 956 migraine codes were identified: 185 per 100 000 deliveries. Diagnoses that were jointly associated with migraine codes during pregnancy (excluding pre-eclampsia) were stroke (odds ratio 15.05, 95% confidence interval 8.26 to 27.4), myocardial infarction/heart disease (2.11, 1.76 to 2.54

BMJ2009 Full Text: Link to full Text with Trip Pro

166. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age

Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age 19255022 2009 03 03 2009 03 30 2013 08 21 1098-4275 123 3 2009 Mar Pediatrics Pediatrics Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. 924-34 10.1542/peds.2008-0642 Currently, no drugs are Food and Drug (...) Administration-approved for migraine prophylaxis in pediatric patients. The objective of this study was to evaluate the efficacy and safety of topiramate for migraine prevention in adolescents. Adolescents (12-17 years of age) with a >/=6-month history of migraine were assigned randomly to receive 16 weeks of daily treatment with topiramate (50 or 100 mg/day) or placebo. The primary efficacy measure was the percent reduction in monthly migraine attacks, with the use of the 48-hour rule, from the prospective

EvidenceUpdates2009

167. Acupuncture for migraine prophylaxis.

Acupuncture for migraine prophylaxis. BACKGROUND: Acupuncture is often used for migraine prophylaxis but its effectiveness is still controversial. This review (along with a companion review on 'Acupuncture for tension-type headache') represents an updated version of a Cochrane review originally published in Issue 1, 2001, of The Cochrane Library. OBJECTIVES: To investigate whether acupuncture is a) more effective than no prophylactic treatment/routine care only; b) more effective than 'sham (...) ' (placebo) acupuncture; and c) as effective as other interventions in reducing headache frequency in patients with migraine. SEARCH STRATEGY: The Cochrane Pain, Palliative & Supportive Care Trials Register, CENTRAL, MEDLINE, EMBASE and the Cochrane Complementary Medicine Field Trials Register were searched to January 2008. SELECTION CRITERIA: We included randomized trials with a post-randomization observation period of at least 8 weeks that compared the clinical effects of an acupuncture

Cochrane2009

168. The relative efficacy of phenothiazines for the treatment of acute migraine: a meta-analysis

The relative efficacy of phenothiazines for the treatment of acute migraine: a meta-analysis The relative efficacy of phenothiazines for the treatment of acute migraine: a meta-analysis The relative efficacy of phenothiazines for the treatment of acute migraine: a meta-analysis Kelly AM, Walcynski T, Gunn B CRD summary The authors concluded that phenothiazines were more effective than placebo for the treatment of migraine headache and had higher rates of clinical success than other agents (...) . These conclusions are supported by the results of the review and are likely to be reliable. Authors' objectives To determine the relative effectiveness of phenothiazines compared with placebo and other active agents for the treatment of acute migraine. Searching MEDLINE, EMBASE, CINAHL and the Cochrane Library databases, plus international clinical trial registers, were searched to December 2008. Search terms were reported. The related articles function in PubMed was used to identify additional studies. Authors

DARE.2009

169. Anticonvulsant drugs for pediatric migraine prevention: an evidence-based review

Anticonvulsant drugs for pediatric migraine prevention: an evidence-based review Anticonvulsant drugs for pediatric migraine prevention: an evidence-based review Anticonvulsant drugs for pediatric migraine prevention: an evidence-based review Bakola E, Skapinakis P, Tzoufi M, Damigos D, Mavreas V CRD summary This review found that the use of anticonvulsants to prevent migraine in children and adolescents was not well supported by the current evidence and more research was needed. The review (...) methods were not clearly reported and there appeared to be some risk of publication bias, but the limitations of the included evidence suggest that the authors' conclusions are justified. Authors' objectives To evaluate the efficacy and safety of anticonvulsants for the prevention of migraine in children and adolescents. Searching PubMed (1966 to September 2008), EMBASE (1980 to 2007) and the Cochrane Central Register of Controlled Trials (CENTRAL; 2008, issue 1) were searched for published studies

DARE.2009

170. Review: adding dexamethasone to standard therapy reduces short-term relapse for acute migraine in the emergency department

Review: adding dexamethasone to standard therapy reduces short-term relapse for acute migraine in the emergency department Review: adding dexamethasone to standard therapy reduces short-term relapse for acute migraine in the emergency departmentCommentary | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: adding dexamethasone to standard therapy reduces short-term relapse for acute migraine in the emergency departmentCommentary Article Text Therapeutics Review: adding dexamethasone to standard therapy reduces short-term relapse for acute migraine

Evidence-Based Medicine (Requires free registration)2009

171. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials

Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials Shuhendler AJ, Lee S, Siu (...) M, Ondovcik S, Lam K, Alabdullatif A, Zhang X, Machado M, Einarson TR CRD summary The review found that there was no statistically significant difference between botulinum toxin type A and placebo in the prophylaxis of episodic migraine. Despite the some minor flaws in the conduct and reporting of the review, the authors’ conclusion appears to be reliable. Authors' objectives To evaluate the efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches. Searching PubMed

DARE.2009

172. Are migraineurs at increased risk of adverse drug responses: a meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine

Are migraineurs at increased risk of adverse drug responses: a meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine Are migraineurs at increased risk of adverse drug responses: a meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine Are migraineurs at increased risk of adverse drug responses: a meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine Luykx J, Mason M, Ferrari (...) M D, Carpay J CRD summary The authors concluded that an equivalent dose of topiramate was associated with different adverse drug reactions and a higher likelihood of drug-related withdrawal from treatment in patients with migraine than in patients with epilepsy. Given the marked differences between trials and the questionable relevance of comparisons made in the review, the reliability and clinical significance of these findings is unclear. Authors' objectives To compare adverse drug reactions

DARE.2009

173. Acupuncture reduced frequency and pain intensity of primary migraine or tension-type headaches

Acupuncture reduced frequency and pain intensity of primary migraine or tension-type headaches Acupuncture reduced frequency and pain intensity of primary migraine or tension-type headaches | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Acupuncture reduced frequency and pain intensity of primary migraine or tension-type headaches Article Text Treatment Acupuncture reduced frequency and pain intensity of primary migraine or tension-type headaches Statistics from Altmetric.com No Altmetric data available

Evidence-Based Nursing (Requires free registration)2009

174. The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials

The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials 18632186 2008 11 25 2008 12 18 2016 11 22 1097-6760 52 6 2008 Dec Annals of emergency medicine Ann Emerg Med The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials. 705-13 10.1016/j.annemergmed.2008.05.036 Despite guidelines recommending against opioids as first-line treatment for acute migraine, meperidine (...) is the agent used most commonly in North American emergency departments. Clinical trials performed to date have been small and have not arrived at consistent conclusions about the efficacy of meperidine. We performed a systematic review and meta-analysis to determine the relative efficacy and adverse effect profile of opioids compared with nonopioid active comparators for the treatment of acute migraine. We searched multiple sources (Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

175. Migraine, vascular risk, and cardiovascular events in women: prospective cohort study.

Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. OBJECTIVES: To evaluate whether the association between migraine with aura and increased risk of cardiovascular disease is modified by vascular risk groups as measured by the Framingham risk score for coronary heart disease. DESIGN: Prospective cohort study. SETTING: Women's health study, United States. PARTICIPANTS: 27 519 women who were free from cardiovascular disease at baseline with available information (...) on the Framingham risk score and migraine status. MAIN OUTCOME MEASURES: Time to major cardiovascular disease event (non-fatal myocardial infarction, non-fatal ischaemic stroke, death from ischaemic cardiovascular disease), myocardial infarction, and ischaemic stroke. RESULTS: At baseline, 3577 (13.0%) women reported active migraine, of whom 1418 (39.6%) reported migraine with aura. During 11.9 years of follow-up, there were 697 cardiovascular disease events. We stratified participants based on 10 year risk

BMJ2008 Full Text: Link to full Text with Trip Pro

176. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine

Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine 18606965 2008 07 08 2008 07 22 2013 11 21 1526-632X 71 2 2008 Jul 08 Neurology Neurology Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. 114-21 10.1212/01.wnl.0000316800.22949.20 Research suggests treating a migraine at the first sign of pain increases the likelihood of the best clinical outcome. To investigate the efficacy and tolerability of a fixed (...) -dose, single-tablet formulation of sumatriptan 85 mg, formulated with RT Technology, and naproxen sodium 500 mg (sumatriptan/naproxen) as early intervention acute therapy for migraine. Patients (aged 18 to 65 years) with International Headache Society-defined migraine with or without aura were enrolled in one of two identically designed, randomized, double-blind, parallel group, placebo-controlled studies. Patients treated a single migraine within 1 hour of onset of migraine head pain and while

EvidenceUpdates2008

177. Normobaric and hyperbaric oxygen therapy for migraine and cluster headache.

Normobaric and hyperbaric oxygen therapy for migraine and cluster headache. BACKGROUND: Migraine and cluster headaches are severe and disabling. Migraine affects up to 18% of women, while cluster headaches are much less common (0.2% of the population). A number of acute and prophylactic therapies are available. Hyperbaric oxygen therapy (HBOT) is the therapeutic administration of 100% oxygen at environmental pressures greater than one atmosphere, while normobaric oxygen therapy (NBOT) is oxygen (...) administered at one atmosphere. OBJECTIVES: To assess the safety and effectiveness of HBOT and NBOT for treating and preventing migraine and cluster headaches. SEARCH STRATEGY: We searched the following in May 2008: CENTRAL, MEDLINE, EMBASE, CINAHL, DORCTIHM and reference lists from relevant articles. Relevant journals were hand searched and researchers contacted. SELECTION CRITERIA: Randomised trials comparing HBOT or NBOT with one another, other active therapies, placebo (sham) interventions

Cochrane2008

178. Exercise in migraine therapy--is there any evidence for efficacy? A critical review

Exercise in migraine therapy--is there any evidence for efficacy? A critical review 18572431 2008 06 20 2008 08 26 2009 02 02 1526-4610 48 6 2008 Jun Headache Headache Exercise in migraine therapy--is there any evidence for efficacy? A critical review. 890-9 Some migraine patients find that regular exercise helps in reducing the frequency of headache attacks. In addition, exercise in migraine is recommended from many headache experts. However, most of these recommendations refer to some (...) anecdotal reports or observational studies in literature stating that regular exercise can reduce the frequency and severity of migraine. The purpose of this review is to investigate whether recommendations for exercise in migraine are based on sufficient data to cope with requirements of an evidence-based modern migraine therapy. The review summarizes and discusses all available trials on this topic. Eight studies und 4 case reports investigated the therapeutic role of aerobic exercise on migraine

EvidenceUpdates2008

179. Botulinum toxin type a as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues

Botulinum toxin type a as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues 18047501 2008 06 13 2008 08 26 2010 11 18 1526-4610 48 6 2008 Jun Headache Headache Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. 900-13 To examine the efficacy and safety of and satisfaction with botulinum toxin type A (BoNTA; BOTOX: Allergan, Inc., Irvine, CA (...) ) for prophylactic treatment of migraine headache in patients previously failing prophylaxis because of issues pertaining to compliance. Background.- Numerous factors (eg, adverse effects, tolerability, cost, frequency of dosage, hesitancy to take daily medication, failure to complete treatment) negatively influence compliance with the preventive pharmacology for migraine prophylaxis. BoNTA may offer benefit in improving compliance because of its long duration of action, injectable route of administration

EvidenceUpdates2008

180. Neuromodulators for migraine prevention

Neuromodulators for migraine prevention 18205800 2008 04 01 2008 06 17 2009 02 02 0017-8748 48 4 2008 Apr Headache Headache Neuromodulators for migraine prevention. 586-600 10.1111/j.1526-4610.2007.01040.x Migraine is a debilitating condition characterized by a cycle of painful headaches and headache-related symptoms interspersed with periods of worry, distress, and apprehension. The negative impact of migraine on patient functioning, workplace productivity, and other daily activities has been (...) demonstrated through the use of a variety of clinician- and patient-reported assessment tools, including the Migraine-Specific Questionnaire and the Migraine Disability Assessment questionnaire. In addition to considering the frequency and severity of migraine, clinicians need to encourage more open dialogue with their patients about the impact of this disorder on daily activities and productivity. Only then can the most appropriate course of treatment be determined. Appropriately prescribed acute

EvidenceUpdates2008